|
DuPont Opens Integrated Knowledge Center In India DuPont India, a
subsidiary of US-based science-based products and services company DuPont, has
opened its integrated knowledge centre - DuPont Knowledge Centre (DKC) - at
Hyderabad to provide basic discovery research and applications development
services.
The new R&D centre, which comes as DuPont's first plant biotech research
centre outside the USA, houses a biotechnology lab, a materials research lab, an
applications development lab, a global engineering design centre and greenhouse
in the fifteen acres premises in the ICICI knowledge Park in Genome Valley,
Hyderabad.
The company is investing Rs 130 crore to construct its first research and
development centre in India with focus on basic research, product application
development across all five of its business growth platforms, and other
knowledge services for global and local markets, announced DuPont.
The DuPont Knowledge Centre brings together basic research, applications
development, engineering design, bioinformatics, patent services and many
regional support services. The new research centre, built on a 'One DuPont'
concept, will focus on integrated science research - unique combination of
biology, chemistry, materials science and engineering - to develop the company's
application pipeline in India and other emerging markets.
"The DuPont Knowledge Centre is a critical component of our growth strategy
and our investment in the DKC further demonstrates our commitment to India,"
said Balvinder S Kalsi, president and chief executive officer, DuPont India. The
centre will enable to increase the 'speed to market' with products that come out
of the R&D and innovations pipeline, not only for India but also for other
growth regions, and help the company in its mission to become a billion dollar
company in its mission to become a billion dollar company, he added.
"We will have under one roof the key science such as organic, inorganic, and
polymer chemistry, biology, and materials science coupled with engineering to
create unique and commercializable solutions," says Homi Bhedwar, director,
Dupont Knowledge Centre.
The DKC, with strength of 180 staff, is expected to accommodate more than 300
scientists, engineers and other employees will eventually work out of the DKC
once it is fully functional, working closely with more than 5,000 scientists of
DuPont located around the world. The facility is designed in a manner that
allows for future expansion, informed DuPont in an announcement.
The DKC is the sixth major DuPont R&D facility outside the United States.
DuPont has more than 50 R&D facilities throughout the world with 20 in the
United States and more than 30 in 11 other nations. In addition to the Central
R&D at the DuPont Experimental Station at Wilmington, USA, other major DuPont
R&D facilities are located in Shanghai, China; Utsunomiya, Japan; Hsinchu,
Taiwan; Wuppertal, Germany and Meyrin, Switzerland.
The company invests an average of $1.3 billion annually on global research
and development in a diverse range of technologies for many markets including
agriculture, automotive, construction, electronics, chemicals and industrial
materials.
(Ref : Chronicle Pharmabiz dated December 4, 2008)
Marck To Set Up Sterile Dosages Facility With Rs 800 Mn
The Ahmedabad-based Marck Biosciences Ltd, a leading manufacturer and
marketer of sterile dosages pharma products, is all set to set up a new facility
to consolidate its position in the growing sterile dosages pharma market. The
company would make an investment of Rs 800 million over the next three years for
this end. The proposed new facility would be used to manufacture a comprehensive
range of formulations and injectables in glass vials, sterile ointments,
mono-dose ophthalmics and an array of lens cleaning solutions for global
markets.
"With a wider and deeper portfolio of sterile dosages products, we will be
able to address a large share of the sterile dosage market with both our own
brand and through contract manufacturing. Marck Biosciences is committed to
consolidate its outsourcing business by leveraging its sterile dosages
expertise. The company's formulation and development is geared to match the
market expectations, offering new product range to frontrunners in the market.
Our existing facility has five blow-fill-seal technology lines. Having
established ourselves in BFS sterile dosages market, we have decided to add new
technological capabilities to manufacture a diverse range of sterile dosages
products under different therapeutic segments," said, Bhavesh Patel, MD, Marck
Biosciences.
(Ref : Chronicle Pharmabiz dated August 28, 2008)
GE Healthcare To Invest $50-60 Mn In India In 3 Years
GE Healthcare is planning an investment of $50-$60 million in India over the
next three years as part of the public-private partnership efforts in the
country. The company will tap the outsourcing opportunities to offer its
radiology technology at the healthcare facilities in 10 states. These will
include tie-ups with both private and government hospitals. The company has
currently inked pact at Madhya Pradesh and Gujarat. There will also be five more
GE installations at the medical college hospitals in Gujarat.
According to V. Raja, president & CEO, GE Healthcare, South Asia, each centre
will need at investment of around $3 million. The biggest challenge in this PPP
initiative is the reach and provide the affordability. There is a huge scope for
us to offer our expertise and this is the only way to ensure early detection of
diseases, he added.
Under the PPP model, GE Healthcare will set up advanced diagnostic imaging
facilities like Bright-Speed Computed Tomography and High Definition Magnetic
Resonance systems in each centre. Additionally, GE Healthcare will facilitate
operation of these centres by engaging, professional radiologists, technicians
and staff. GE Healthcare will facilitate training of staff and students, after
sales service and so on to ensure high uptime of these equipments.
The tripartite pact by GE Healthcare with the state Governments and the
healthcare providers provide reasonable healthcare costs using advanced
technology.
(Ref : Chronicle Pharmabiz dated October 2, 2008) |
